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Abstract
We observed pediatric S. aureus hospitalizations decreased 36% from 26.3 to 16.8 infections per 1,000 admissions from 2009 to 2016, with
methicillin-resistant S. aureus (MRSA) decreasing by 52% and methicillin-susceptible S. aureus decreasing by 17%, among 39 pediatric
hospitals. Similar decreases were observed for days of therapy of anti-MRSA antibiotics.
(Received 14 May 2018; accepted 9 September 2018; electronically published October 29, 2018)
Staphylococcus aureus (S. aureus) causes a substantial number of
pediatric infections each year in the United States, with potential
for severe complications including death.1–4 Although the emer-
gence of methicillin-resistant S. aureus (MRSA) led to a rapid
increase in the number of S. aureus infections in children,5 recent
data suggest that S. aureus infections are declining in adults,
driven primarily by decreases in MRSA.6,7 Similar findings have
been reported in pediatric populations, but these studies were
limited to single centers and unique populations, such as military
members or infants.4,5,8–10 A nationally representative and con-
temporary characterization of epidemiologic trends in S. aureus
infections has not been conducted. The objective of this study was
to describe recent trends in pediatric S. aureus hospitalizations
and associated antibiotic prescribing patterns.
Patients and Methods
Data source and quality
We conducted a retrospective cohort study using the Pediatric
Health Information Systems (PHIS) administrative database,
maintained by the Children’s Hospital Association (Overland
Park, KS). PHIS includes clinical and resource utilization data
from inpatient, emergency, ambulatory surgery, and observation
units at more than 45 tertiary-care freestanding children’s hos-
pitals in the United States. The data are subject to numerous
validity and reliability checks before incorporation into the
database. The data warehouse function was provided by Truven
Health Analytics (Ann Arbor, MI).
Study population
All inpatient encounters for patients <18 years of age hospitalized
between January 1, 2009, and December 31, 2016, at a PHIS
hospital with continuous reporting were included. The study
population was limited to patients with an S. aureus infection
indicated in the electronic medical record, defined as (1) having
≥1 International Classification of Disease, Clinical Modifications
version 9 or version 10 discharge code for MRSA (038.12, 041.12,
482.42, A41.02, A49.02, B95.62, J152.12, V02.54) or methicillin-
susceptible S. aureus (MSSA) (038.11, 041.11, 482.41, A41.01,
A49.01, B95.61, J152.11, V02.53) present on admission or
occurring during the admission; and (2) receiving ≥1 anti-
staphylococcal antibiotic (list available upon request). Using
additional discharge codes when present, S. aureus infections
were further stratified into 4 infection categories: (1) skin or soft-
tissue infection (SSTI); (2) myositis/osteomyelitis/septic arthritis;
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(3) bacteremia/endocarditis; or (4) pneumonia.10 Patients could
be assigned >1 category.
Data analysis
The annual rates for S. aureus overall, MRSA, and MSSA were
calculated per 1,000 hospital admissions. Trends in hospitalization
rates over time were analyzed using the Cochran-Armitage trend
test, with 2-sided P values reported and statistical significance set
at P< .05. Median and interquartile ranges (IQR) are reported for
continuous variables. Antibiotic days of therapy (DOT) per 1,000
patient days were evaluated, where the DOT numerator is the
aggregate sum of anti-staphylococcal antibiotics used per patient
with S. aureus infections per day and the denominator is the total
hospital inpatient days for all hospitalized patients, analyzed
separately for antibiotics with activity against MRSA. Data ana-
lyses were performed with SAS version 9.4 software (SAS Insti-
tute, Cary, NC). The Institutional Review Board of Children’s
Minnesota Hospital deemed this study exempt from review.
Results
Among 39 hospitals with continuous reporting to PHIS from
2009 to 2016, we identified 116,152 S. aureus hospitalizations.
Among patients with S. aureus hospitalizations, the median age
was 3 years (IQR, 0–11 years), 53.7% were male, 52.5% were
white, and 18.8% were African American. The median length of
hospital stay was 5 days (IQR, 2–13 days), with intensive care unit
admissions occurring in 26.3% of MSSA hospitalizations com-
pared with 22.3% of MRSA hospitalizations (Table 1).
From 2009 to 2016, pediatric S. aureus hospitalizations
decreased 36% from 26.3 to 16.8 infections per 1,000 admissions
(P< .001) (Fig. 1A). Overall, there was a 52% decrease in MRSA
infections (14.4 to 6.9 infections per 1,000 admissions; P< .001)
and a 17% decrease in MSSA infections (11.9 to 9.9 infections per
1,000 admissions; P< .001). In 2009, 55% of all S. aureus infec-
tions were MRSA, and this rate decreased to 41% in 2016.
MRSA infections were most often categorized as SSTIs
(44.7%), followed by myositis/osteomyelitis/septic arthritis
(7.1%), bacteremia/endocarditis (4.5%), and pneumonia (4.8%);
44.3% of MRSA infections were not categorized. Although rates in
all MRSA categories decreased over time, the decrease was most
notable among SSTIs, which decreased from 7.3 in 2009 to 2.9
infections per 1,000 admissions in 2016 (P< .001); other MRSA
categories remained relatively unchanged. Notably the proportion
of MRSA infections decreased among non-Hispanic African
Americans (22.9% to 19.1% from 2009 to 2016; P< .001), 1–5-
year-olds (39% to 32.1% from 2009 to 2016; P< .001), and among
patients from the South (47.2% to 43.8%; P< .001).
MSSA infection categories were similar to MSRA in distribu-
tion. Over time, these decreases were most notable among SSTIs
(from 4.1 in 2009 to 2.9 in 2016; P< .001) and bacteremia/
endocarditis infections (from 1.2 in 2009 to 0.6 in 2016; P< .001).
The antibiotics most commonly used to treat S. aureus
infections were vancomycin (14.9% of DOT per 1,000 patient
days), clindamycin (11.3%), cefazolin (4.1%), trimethoprim/sul-
famethoxazole (TMP/SMX) (4.1%), and ceftriaxone (2.4%).
Vancomycin and clindamycin remained the 2 most commonly
prescribed antibiotics over the study period. Days of therapy per
1,000 patient days among antibiotics with activity against MRSA
specifically decreased from 38.0 to 24.5, with the most notable
Table 1. Demographics of Pediatric Patients With Staphylococcus aureus













Female 53,773 (46.3) 28,582 (47.8) 25,191 (44.7)
Male 62,379 (53.7) 31,180 (52.2) 31,199 (55.3)
Age
Median (IQR), y 3 (0–11) 3 (1–11) 4 (0–11)
<1 y 29,336 (25.3) 14,453 (24.2) 14,883 (26.4)
1–5 y 37,509 (32.3) 21,446 (35.9) 16,063 (28.5)
6–12 y 26,092 (22.5) 12,462 (20.9) 13,630 (24.2)
13–17 y 23,215 (20) 11,401 (19.1) 11,814 (21)
Race and ethnicity
White 61,020 (52.5) 31,823 (53.2) 29,197 (51.8)
African American 21,855 (18.8) 12,316 (20.6) 9,539 (16.9)
Hispanic 20,366 (17.5) 9,738 (16.3) 10,628 (18.8)
Asian American 2,387 (2.1) 839 (1.4) 1,548 (2.7)
Other 10,524 (9.1) 5,046 (8.4) 5,478 (9.7)
Census region
Midwest 31,285 (26.9) 16,166 (27.1) 15,119 (26.8)
Northeast 13,818 (11.9) 6,122 (10.2) 7,696 (13.6)
South 46,462 (40) 26,446 (44.3) 20,016 (35.5)
West 24,587 (21.2) 11,028 (18.5) 13,559 (24.0)
Health insurance payer
Private 37,297 (32.1) 17,041 (28.5) 20,256 (35.9)
Government 72,619 (62.5) 39,370 (65.9) 33,249 (59)
Other payer 6,236 (5.4) 3,351 (5.6) 2,885 (5.1)
Hospital-encounter
variables
Length of hospital stay
Median (IQR), d 5 (2–13) 4 (2–12) 5 (3–14)
ICU or NICU stay 28,137 (24.2) 13,321 (22.3) 14,816 (26.3)
Primary reason for visit
Medical 85,895 (74) 45,466 (76.1) 40,429 (71.7)
Surgical 30,257 (26) 14,296 (23.9) 15,961 (28.3)
Any complex chronic
condition
54,517 (46.9) 26,569 (44.5) 27,948 (49.6)
Crude mortality 1,850 (1.6) 754 (1.3) 1,096 (1.9)
30-day all-cause
readmission rate
13,858 (11.9) 6,604 (11.1) 7,254 (12.9)
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decreases for clindamycin (14.32 to 7.5) and vancomycin (16.6 to
10.8) (Fig. 1B).
Discussion
In this study, we observed a 36% decrease for S. aureus hospi-
talizations between 2009 and 2016. Notably, MRSA hospitaliza-
tions decreased 52%, including a corresponding decrease in DOT
for anti-MRSA antibiotics during the same period.
Decreases in S. aureus hospitalizations detected in this study
were similar to findings from studies performed in other adult
and pediatric inpatient populations.6,7 A number of factors may
contribute to these decreases: (1) earlier recognition of S. aureus
infections (especially SSTIs) and initiation of appropriate
therapy in outpatient settings, such as incision and drainage
and/or targeted antibiotic therapy which might prevent hospi-
talization and/or recurrences; (2) changes in the tendency to
hospitalize patients with suspected staphylococcal infections
such as SSTIs presenting to emergency departments; (3)
increased provider confidence to manage infections in the
outpatient settings, and (4) the possibility of reductions in
transmission of MRSA due to better infection control strategies
especially in community settings or due to changes in circu-
lating MRSA clones or lower prevalence in the community.
Future studies are warranted to determine whether MRSA
infections at the community-level are also decreasing, how to
best measure the impact of infection control practices, and how
SSTI visits in the emergency department might have also
changed over time.
This study has several limitations. First, we identified cases of
S. aureus using administrative coding and, though this method
has been used in other studies, it has not been validated. To
enhance specificity, we included an additional requirement of
receipt of an antibiotic with activity against S. aureus during the
hospitalization. Second, PHIS only includes hospitalized patients
and therefore does not allow us to distinguish between hospital-
onset versus community-onset infections or to address
concurrent trends in outpatient care settings that might have
contributed to our findings. When we looked at our “present on
admission” flag, we found only 9.3% of all S. aureus infections
were marked as “no.” Third, the generalizability of our findings to
pediatric hospitalizations outside of freestanding children’s hos-
pitals is uncertain including the possibility that some S. aureus
hospitalizations may have shifted to hospitals not captured
by PHIS.
Despite these limitations, these results provide evidence of
substantial and sustained decreases in pediatric S. aureus hospi-
talizations, driven by declining MRSA hospitalizations. Further











S. aureus infection category
SSTI 45,148 (38.9) 26,709 (44.7) 18,439 (32.7)
Myositis/osteomyelitis/
septic arthritis
11,750 (10.1) 4,231 (7.1) 7,519 (13.3)
Bacteremia/endocarditis 8,140 (7) 2,717 (4.5) 5,423 (9.6)
Pneumonia 9,174 (7.9) 2,861 (4.8) 6,313 (11.2)





Top 5 antibiotics prescribed
during hospital admission
Clindamycin 64,059 (55.2) 35,874 (60) 28,185 (50)
Vancomycin 51,047 (43.9) 26,967 (45.1) 24,080 (42.7)
Cefazolin 25,131 (21.6) 7,111 (11.9) 18,020 (32)
Ceftriaxone 17,732 (15.3) 7,846 (13.1) 9,886 (17.5)
TMP/SMX 15,856 (13.7) 9,712 (16.3) 6,144 (10.9)
Note. IQR, interquartile range; ICU, intensive care unit; NICU, neonatal intensive care unit;
SSTI, skin and soft-tissue infection; DOT, days of therapy; TMP/SMX, trimethoprim/sulfa-
methoxazole.
aAll differences between groups were statistically significant.
bUnless otherwise specified.
Fig. 1. (A) S. aureus hospitalization rate per 1,000 hospital admissions in 39 PHIS
hospitals with continuous reporting, 2009–2016. (B) Days of therapy for the most
commonly used antibiotics per patient day among S. aureus hospital admissions.
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research is necessary to better understand the factors driving
these epidemiologic changes.
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